ReviewWorld journal of clinical cases2014
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.
Review in World journal of clinical cases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
176 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Population structure discovery in meta-analyzed microbial communities and inflammatory bowel disease using MMUPHin.Genome biology · 2022Pooled it
- Review
- Integrated in-silico and in-vitro evaluation of silybin as a potential quorum-sensing modulator against Acinetobacter baumannii and Staphylococcus aureus.World journal of microbiology & biotechnology · 2026Article
- A Rapid Screening Strategy for Secondary Bacteriophages to Counter Phage Resistance in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Deciphering synergistic killing mechanisms of capsaicin combined with colistin against colistin-resistantBiochemistry and biophysics reports · 2026Article
- Decoding the genome of Acinetobacter baumannii from a urinary tract infection case: A comprehensive analysis of resistance, virulence, and genetic mobility attributes.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Effect of polymyxin resistance evolution on the fitness costs of Acinetobacter baumannii and the underlying mechanisms of polymyxin resistance.Scientific reports · 2026Article
- Comprehensive Molecular Characterization of Extensively Drug-ResistantPharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Prophylactic and therapeutic efficacy of Acinetobacter phage RM_A1 against carbapenem-resistant Acinetobacter baumannii with no cytotoxicity to human skin cells.BMC microbiology · 2026Article
- Molecular analysis of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- CLEC3A-derived peptides exhibit broad-spectrum activity againstFrontiers in cellular and infection microbiology · 2026Article
- Epidemiology and molecular typing of multidrug resistant Acinetobacter baumannii burn wound isolates from six Chinese provinces.Scientific reports · 2025Article
- Emerging virulent clones of community-onset Acinetobacter baumannii in Taiwan.Tropical medicine and health · 2025Article
- Molecular identification and antimicrobial evaluation of Pistacia atlantica essential oil against multidrug-resistant Acinetobacter baumannii.Molecular biology reports · 2025Article
- Biofilm and Outer Membrane Vesicle Formation in ESKAPE Gram-Negative Bacteria: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Evaluation of antibacterial and antibiofilm efficacy of gentamicin-loaded solid lipid nanoparticles (GM-SLNs) against Acinetobacter baumannii infections.BMC chemistry · 2025Article
- Review
- Assessment of the Antimicrobial Resistance Spectrum and Identification of Extended-spectrum ß-lactamase (ESBL) inArchives of Razi Institute · 2025Article
116 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii (A. baumannii) is undoubtedly one of the most successful pathogens in the modern healthcare system. With invasive procedures, antibiotic use and immunocompromised hosts increasing in recent years, A. baumannii has become endemic in hospitals due to its versatile genetic machinery, which allows it to quickly evolve resistance factors, and to its remarkable ability to tolerate harsh environments. Infections and outbreaks caused by multidrug-resistant A. baumannii (MDRAB) are prevalent and have been reported worldwide over the past twenty or more years. To address this problem effectively, knowledge of species identification, typing methods, clinical manifestations, risk factors, and virulence factors is essential. The global epidemiology of MDRAB is monitored by persistent surveillance programs. Because few effective antibiotics are available, clinicians often face serious challenges when treating patients with MDRAB. Therefore, a deep understanding of the resistance mechanisms used by MDRAB can shed light on two possible strategies to combat the dissemination of antimicrobial resistance: stringent infection control and antibiotic treatments, of which colistin-based combination therapy is the mainstream strategy. However, due to the current unsatisfying therapeutic outcomes, there is a great need to develop and evaluate the efficacy of new antibiotics and to understand the role of other potential alternatives, such as antimicrobial peptides, in the treatment of MDRAB infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.